IP Library Granted Patent US 7,413,652
Granted Patent B2
US 7,413,652 · App. 11/115,076 · Granted Aug 19, 2008

Method for the production of a blood component composition

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,413,652
App. No.
11/115,076
Granted
Aug 19, 2008
Kind
B2
Abstract

A system for the production of a blood component composition is provided. The system includes a centrifuge having a blood reservoir for receiving and separating a blood sample into multiple components; a dispenser disposed outside of the centrifuge having a first collection chamber containing an activation agent and a second collection chamber containing one or more medicinal agents; means for removing a first portion at least one separated blood component from the centrifuge to the first container and a second portion to the second collection chamber, wherein the first collection chamber activates the first portion and stores the resulting clot and thrombin; a filter for separating the thrombin from the clot; and a nozzle for entraining and mixing the thrombin with the second portion containing the one or more medicinal components.

Claims (14)

1. A system of the production of a blood component composition, comprising:

a centrifuge including a blood reservoir for receiving and separating an anticoagulated blood sample having multiple inactive blood components;

a dispenser being disposed outside of the centrifuge and the blood reservoir and having first collection chamber containing an activation agent and a second collection chamber containing one or more medicinal materials;

means for removing at least one of the inactive blood component upon separation from the centrifuge and delivering a first portion of the inactive blood component to the first collection chamber and a second portion of the inactive blood component to the second collection chamber, the first collection chamber activating the first portion of the inactive blood component and storing a resulting activated blood component comprising a clot and thrombin, the second collection chamber combining the second portion of the inactive blood component with the one or more medicinal materials;

a filter for separating the thrombin from the clot; and

a nozzle for entraining and mixing the thrombin with the second portion of the inactive blood component comprising the one or more medicinal materials thereby forming the blood component composition.

2. The system of claim 1 , wherein the blood sample is separated into various inactive blood components comprising a red blood cell component, a white blood cell component, a platelet rich plasma component and a platelet poor plasma component.

3. The system of claim 1 , wherein the first collection chamber contains a restoration agent.

4. The system of claim 3 , wherein the restoration agent is a calcium salt or an anti-heparmn agent.

5. The system of claim 4 , wherein the calcium salt is calcium chloride, calcium gluconate, or calcium carbonate.

6. The system of claim 4 , wherein the anti-heparin agent is heparinase or protamine.

7. The system of claim 1 , wherein the activation agent is glass wool, silica, aluminum, diatomaceous earth, kaolin, plastic, siliconized glass or a chemical activator.

8. The system of claim 1 , wherein the one or more medicinal materials are selected from the group consisting of drugs, analgesic compounds, antibacterial compounds, antibiotics, antifungal compounds, anti-inflammatories, antiparasitic compounds, antiviral compounds, anticancer compounds, genetic agents, enzyme inhibitors, glycoproteins, growth factors, hormones, steroids, glucocorticosteroids, immunomodulators, immunoglobulins, minerals, neuroleptics, proteins, peptides, lipoproteins, tumoricidal compounds, tumorstatic compounds, toxins, vitamins, bone, gelatin, collagen, degradable polymers, hyaluronic acid, carbohydrates and starches.

9. The system of claim 1 , wherein the means for removing at least one of said separated inactive blood component from the centrifuge and delivering a first portion of the inactive blood component to the first collection chamber and a second portion of the inactive blood component to the second collection chamber comprises a lumen.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Oct 18, 2023
From: TWIN BROOK CAPITAL PARTNERS, LLC
To: ISTO TECHNOLOGIES II, LLC
Reel/Frame 065269/0604 →
SECURITY INTEREST Recorded Aug 29, 2016
From: ARTERIOCYTE MEDICAL SYSTEMS, INC.
To: TWIN BROOK CAPITAL PARTNERS, LLC, AS AGENT
Reel/Frame 039567/0894 →
RELEASE OF SECURITY INTEREST Recorded Apr 7, 2016
From: COMERICA BANK
To: ARTERIOCYTE MEDICAL SYSTEMS MANUFACTURING OF MASSACHUSETTS INCORPORATED
Reel/Frame 038381/0895 →
RELEASE OF SECURITY INTEREST Recorded Mar 28, 2016
From: ESCALATE CAPITAL PARTNERS SBIC I, L.P.
To: ARTERIOCYTE MEDICAL SYSTEMS, INC.
Reel/Frame 038113/0976 →
SECURITY INTEREST Recorded Nov 5, 2014
From: ARTERIOCYTE MEDICAL SYSTEMS, INC.
To: COMERICA BANK
Reel/Frame 034170/0303 →
SECURITY INTEREST Recorded Mar 27, 2014
From: ARTERIOCYTE MEDICAL SYSTEMS, INC.
To: ESCALATE CAPITAL PARTNERS SBIC I, L.P.
Reel/Frame 032538/0560 →